Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo

Human Gene Therapy

Volumn 17, Issue 3, 2006, Pages 334-346

  Singh, Narendra P ^a,b   Miller, Robert W ^c   Yolcu, Esma S ^a   Kilinc, Mehmet O ^a   Oechsli, Margaret ^d   Huseby, Rolf ^c   Taylor, Douglas D ^e   Perry, M Theresa ^a   Larocca, Renato V ^f   Shirwan, Haval ^a,e  

^a University of Louisville School of Medicine   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c ApoImmune Inc   (United States)

^d JEWISH HOSPITAL   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f Kentuckiana Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BIOTIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; STREPTAVIDIN;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CELL KILLING; CELL MEMBRANE; CHIMERA; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IRRADIATION; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; STREPTAVIDIN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 33645450748     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.334     Document Type: Article

References (51)

1. ABKEN, H., HOMBACH, A., HEUSER, C., KRONFELD, K., and SELIGER, B. (2002). Tuning tumor-specific T-cell activation: A matter of costimulation? Trends Immunol. 23, 240-245.
2. ALLISON, J.P., and KRUMMEL, M.F. (1995). The Yin and Yang of T cell costimulation. Science 270, 932-933.
3. ANTONIA, S.J., and SEIGNE, J.D. (2000). B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J. Urol. 18, 157-163.
4. ANTONIA, S.J., SEIGNE, J., DIAZ, J., MURO-CACHO, C., EXTERMANN, M., FARMELO, M.J., FRIBERG, M., ALSARRAJ, M., MAHANY, J.J., POW-SANG, J., CANTOR, A., and JANSSEN, W. (2002). Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167, 1995-2000.
5. ANTONIA, S.J., MULE, J.J., and WEBER, J.S. (2004). Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 16, 130-136.
6. APPLEMAN, L.J., TZACHANIS, D., GRADER-BECK, T., VAN PUIJENBROEK, A.A., and BOUSSIOTIS, V.A. (2001). Helper T cell anergy: From biochemistry to cancer pathophysiology and therapeutics. J. Mol. Med. 78, 673-683.
7. ASKENASY, N., YOLCU, E.S., WANG, Z., and SHIRWAN, H. (2003). Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 107, 41-47.
8. BRIONES, J., TIMMERMAN, J.M., PANICALLI, D.L., and LEVY, R. (2003). Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J. Natl. Cancer Inst. 95, 548-555.
9. CHAKRABORTY, N.G., STEVENS, R.L., MEHROTRA, S., LASKA, E., TAXEL, P., SPORN, J.R., SCHAUER, P., and ALBERTSEN, P.C. (2003). Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol. Immunother. 52, 497-505.
10. CHEN, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336-347.
11. DOLS, A., SMITH, J.W., MEIJER, S.L., FOX, B.A., HU, H.M., WALKER, E., ROSENHEIM, S., MOUDGIL, T., DORAN, T., WOOD, W., SELIGMAN, M., ALVORD, W.G., SCHOOF, D., and URBA, W.J. (2003). Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results. Hum. Gene Then 14, 1117-1123.
12. FELZMANN, T., RAMSEY, W.J., and BLAESE, R.M. (1999). Antitumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett. 135, 1-10.
13. FINN, O.J. (2003). Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 3, 630-641.
14. GASTMAN, B.R., ATARSHI, Y., REICHERT, T.E., SAITO, T., BALKIR, L., RABINOWICH, H., and WHITESIDE, T.L. (1999). Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59, 5356-5364.
15. GEIGER, J.D., HUTCHINSON, R.J., HOHENKIRK, L.F., MCKENNA, E.A., YANIK, G.A., LEVINE, J.E., CHANG, A.E., BRAUN, T.M., and MULE, J.J. (2001). Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61, 8513-8519.
16. GRAKOUI, A., BROMLEY, S.K., SUMEN, C., DAVIS, M.M., SHAW, A.S., ALLEN, P.M., and DUSTIN, M.L. (1999). The immunological synapse: A molecular machine controlling T cell activation. Science 285, 221-227.
17. GUINN, B.A., DEBENEDETTE, M.A., WATTS, T.H., and BERINSTEIN, N.L. (1999). 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162, 5003-5010.
18. HALAK, B.K., MAGUIRE, H.C., JR., and LATTIME, E.C. (1999). Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59, 911-917.
19. HORIG, H., LEE, D.S., CONKRIGHT, W., DIVITO, J., HASSON, H., LAMARE, M., RIVERA, A., PARK, D., TINE, J., GUITO, K., TSANG, K.W., SCHLOM, J., and KAUFMAN, H.L. (2000). Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.I co-stimulatory molecule. Cancer Immunol. Immunother. 49, 504-514.
20. HOUGHTON, A.N. (2004). LIGHTing the way for tumor immunity. Nat. Immunol. 5, 123-124.
21. ISHIGAMI, S., NATSUGOE, S., TOKUDA, K., NAKAJO, A., HIGASHI, H., IWASHIGE, H., ARIDOME, K., HOKITA, S., and AIKOU, T. (2002). CD3-ζ chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94, 1437-1442.
22. JENKINS, M.K., and SCHWARTZ, R.H. (1987). Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319.
23. JOKI, T., KIKUCHI, T., AKASAKI, Y., SAITOH, S., ABE, T., and OHNO, T. (1999). Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int. J. Cancer 82, 714-720.
24. LAFFERTY, K.J., PROWSE, S.J., and SIMEONOVIC, C.J. (1983). Immunobiology of tissue transplantation: A return to the passenger leukocyte concept. Annu. Rev. Immunol. 1, 143-173.
25. LANG, S., ATARASHI, Y., NISHIOKA, Y., STANSON, J., MEIDENBAUER, N., and WHITESIDE, T.L. (2000). B7.1 on human carcinomas: Costimulation of T cells and enhanced tumor-induced T-cell death. Cell Immunol. 201, 132-143.
26. LEE, P.P., YEE, C., SAVAGE, P.A., FONG, L., BROCKSTEDT, D., WEBER, J.S., JOHNSON, D., SWETTER, S., THOMPSON, J., GREENBERG, P.D., ROEDERER, M., and DAVIS, M.M. (1999). Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685.
27. LENSCHOW, D.J., WALUNAS, T.L., and BLUESTONE, J.A. (1996). CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258.
28. MARTIN-FONTECHA, A., MORO, M., CROSTI, M.C., VEGLIA, F., CASORATI, G., and DELLABONA, P. (2000). Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity. J. Immunol. 164, 698-704.
29. MAZZOCCHI, A., MELANI, C., RIVOLTINI, L., CASTELLI, C., DEL VECCHIO, M., LOMBARDO, C., COLOMBO, M.P., and PARMIANI, G. (2001). Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: Enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol. Immunother. 50, 199-211.
30. MITCHELL, M.S., DARRAH, D., YEUNG, D., HALPERN, S., WALLACE, A., VOLAND, J., JONES, V., and KAN-MITCHELL, J. (2002). Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20, 1075-1086.
31. OCHSENBEIN, A.F., SIERRO, S., ODERMATT, B., PERICIN, M., KARRER, U., HERMANS, J., HEMMI, S., HENGARTNER, H., and ZINKERNAGEL, R.M. (2001). Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064.
32. PARDOLL, D.M. (2002). Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2, 227-238.
33. PHAN, G.Q., TOULOUKIAN, C.E., YANG, J.C., RESTIFO, N.P., SHERRY, R.M., HWU, P., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J., SEIPP, C.A., FREEZER, L.J., MORTON, K.E., MAVROUKAKIS, S.A., WHITE, D.E., and ROSENBERG, S.A. (2003). Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 26, 349-356.
34. PLATSOUCAS, C.D., FINCKE, J.E., PAPPAS, J., JUNG, W.J., HECKEL, M., SCHWARTING, R., MAGIRA, E., MONOS, D., and FREEDMAN, R.S. (2003). Immune responses to human tumors: Development of tumor vaccines. Anticancer Res. 23, 1969-1996.
35. RAEZ, L.E., CASSILETH, P.A., SCHLESSELMAN, J.J., PADMANABHAN, S., FISHER, E.Z., BALDIE, P.A., SRIDHAR, K., and PODACK, E.R. (2003). Induction of CD8 T-cell-IFN-γ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther. 10, 850-858.
36. RAEZ, L.E., CASSILETH, P.A., SCHLESSELMAN, J.J., SRIDHAR, K., PADMANABHAN, S., FISHER, E.Z., BALDIE, P.A., and PODACK, E.R. (2004). Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 2800-2807.
37. REICHERT, T.E., DAY, R., WAGNER, E.M., and WHITESIDE, T.L. (1998). Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 58, 5344-5347.
38. RIBAS A., BUTTERFIELD, L.H., GLASPY, J.A., and ECONOMOU, J.S. (2003). Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21, 2415-2432.
39. ROMERO, P., DUNBAR, P.R., VALMORI, D., PITTET, M., OGG, G.S., RIMOLDI, D., CHEN, J.L., LIENARD, D., CEROTTINI, J.C., and CERUNDOLO, V. (1998). Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188, 1641-1650.
40. ROSENBERG, S.A. (2001). Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
41. SALGIA, R., LYNCH, T., SKARIN, A., LUCCA, J., LYNCH, C., JUNG, K., HODI, F.S., JAKLITSCH, M., MENTZER, S., SWANSON, S., LUKANICH, J., BUENO, R., WAIN, J., MATHIESEN, D., WRIGHT, C., FIDIAS, P., DONAHUE, D., CLIFT, S., HARDY, S., NEUBERG, D., MULLIGAN, R., WEBB, I., SUGARBAKER, D., MIHM, M., and DRANOFF, G. (2003). Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630.
42. SCHENDEL, D.J., FRANKENBERGER, B., JANTZER, P., CAYEUX, S., NOBETANER, E., WILLIMSKY, G., MAGET, B., POHLA, H., and BLANKENSTEIN, T. (2000). Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther. 7, 2007-2014.
43. SINGH, N.P., YOLCU, E.S., TAYLOR, D.D., GERCEL-TAYLOR, C., METZINGER, D.S., DREISBACH, S.K., and SHIRWAN, H. (2003). A novel approach to cancer immunotherapy: Tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 63, 4067-4073.
44. SUMIMOTO, H., TANI, K., NAKAZAKI, Y., TANABE, T., HIBINO, H., HAMADA, H., AZUMA, M., and ASANO, S. (1997). GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. Int. J. Cancer 73, 556-561.
45. TERABE, M., and BERZOFSKY, J.A. (2004). Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16, 157-162.
46. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
47. - effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62, 1743-1750.
48. VITALE, M., REZZANI, R., RODELLA, L., ZAULI, G., GRIGOLATO, P., CADEI, M., HICKLIN, D.J., and FERRONE, S. (1998). HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58, 737-742.
49. WILCOX, R.A., FLIES, D.B., ZHU, G., JOHNSON, A.J., TAMADA, K., CHAPOVAL, A.I., STROME, S.E., PEASE, L.R., and CHEN, L. (2002). Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659.
50. YOLCU, E.S., ASKENASY, N., SINGH, N.P., CHERRADI, S.E., and SHIRWAN, H. (2002). Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17, 795-808.
51. YU, P., LEE, Y., LIU, W., CHIN, R.K., WANG, J., WANG, Y., SCHIETINGER, A., PHILIP, M., SCHREIBER, H., and FU, Y.X. (2004). Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5, 141-149.